ClinicalTrials.gg
Active, not recruitingNCT05057013Updated Aug 11, 2025

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

A Phase 1/2 interventional study of HMBD-001 and HMBD-001 and enzalutamide in Bladder Cancer, Triple Negative Breast Cancer and Castration-resistant Prostate Cancer, sponsored by Cancer Research UK. Active, not recruiting at 4 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Cancer Research UK · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 141 studies in Urinary Bladder Neoplasms with a site in United Kingdom — 32 open to participants now, 52 under way, 14 of them phase 3. Urinary Bladder Neoplasms · United Kingdom.

Planned enrollment
88th of 117
81 · median 220
Started
2021
with 12 others
Phase 1/2
18 of 141
4 open now
Primary completion
2025-11
later than 13 of 51 live
Registered
108th of 141
by date
Lead sponsor
5 of 141
Cancer Research UK

Among the 141 studies in Urinary Bladder Neoplasms with a site in United Kingdom, this one is the 88th largest by planned enrollment of the 117 interventional ones that give a count, is one of 13 that started in 2021, is one of 18 in phase 1/2, reaches primary completion later than 13 of the 51 other live ones, and was the 108th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

32 of the 141 studies in Urinary Bladder Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Urinary Bladder Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours. The main aims are to find out the best dose of HMBD-001 that can be given to participants alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how they can be treated, and what happens to HMBD-001 inside the body and how it affects cancer cells.

Read the detailed description

HMBD-001 is a type of drug called a monoclonal antibody. It works by targeting a protein called HER3, which is found in high numbers in some types of cancers including those that contain fusions in a gene called NRG1. By attaching itself to this protein, it may then work to kill the cancer cells or to stop them growing.

This is a first-in-human clinical trial that has two parts:

Part A is a 'dose escalation' phase where small groups of participants will receive increasing doses of HMBD-001 on its own (as a single agent) to find the safest dose that best targets cancer cells.

Part B is a 'dose expansion' phase where larger groups of participants with specific cancer types that are known to have high levels of the protein HER3 or that have a confirmed NRG1 gene fusion will receive the highest doses of HMBD-001 considered to be safe as monotherapy from Part A in combination with other anti-cancer drugs that are already licensed for use.

In Part B Arm 1, participants will receive HMBD-001 in combination with enzalutamide. Enzalutamide is a drug used to treat prostate cancer. Prostate cancer is known to be sensitive to androgens (hormones associated with male characteristics), and enzalutamide blocks the action of androgens by limiting the binding of androgens to androgen receptors. This slows the growth of prostate cancer cells and may kill them.

The main aims of the clinical trial are to find out:

  • The best dose of HMBD-001 alone and in combination with other anti-cancer drugs that should be given to participants.
  • More about the potential side effects of HMBD-001 when given alone and in combination with other anti-cancer agents, and how they can be managed.
  • What happens to HMBD-001 inside the body and how it affects cancer cells.
  • The potential anti-tumour activity of HMBD-001 as a single agent and in combination with other anti-cancer agents in specific tumour types of HER3-expressing tumours or tumours with NRG1 gene fusions.
03

Conditions studied

  • Bladder Cancer
  • Triple Negative Breast Cancer
  • Castration-resistant Prostate Cancer
  • Cervical Cancer
  • RAS Wild Type Colorectal Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Hepatocellular Carcinoma (HCC)
  • Melanoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Oesophageal Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Squamous Cell Cancer of the Head and Neck

Keywords

  • Antibodies, monoclonal
  • HER3
  • Receptor, ErbB-3
  • NRG1
  • NRG1 gene fusion
  • Neuregulin 1
  • Androgen receptor antagonists
  • Prostatic neoplasms, castration-resistant
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written (signed and dated) and be capable of co-operating with HMBD-001 administration and follow-up.
  2. Part A: Monotherapy Dose Escalation

    confirmed advanced or solid tumours resistant or to conventional treatment, or for which no conventional therapy exists or is not considered appropriate by the Investigator or is declined by the participant.

    Participants with tumour types known to overexpress HER3 including:

    • Bladder cancer
    • Triple negative breast cancer
    • Castration resistant prostate cancer
    • Cervical cancer
    • RAS wild type colorectal cancer
    • Endometrial cancer
    • Gastric cancer
    • Hepatocellular carcinoma (HCC)
    • Melanoma
    • Non-small cell lung cancer (NSCLC)
    • Oesophageal cancer
    • Ovarian cancer
    • Pancreatic cancer
    • Squamous cell cancers of the head and neck

    Participants with a confirmed existing NRG1 fusion rearrangement or HER amplification will also be considered eligible.

    Part B Arm 1: HMBD-001 and Enzalutamide Combination

    • Histologically confirmed metastatic castration-resistant prostate adenocarcinoma without neuroendocrine differentiation or small-cell features.
    • Serum testosterone concentration ≤50 ng/dL sustained by medical or surgical castration.
    • Participants must have progressive disease prior to study enrolment.
    • PSA at screening ˃1 ng/mL.
    • Confirmed high HER3 expression.
    • Absence of PTEN loss.
    • Participants with confirmed existing NRG1 fusion rearrangement will also be considered eligible.
  3. of at least 12 weeks.
  4. performance status of 0 or 1.
  5. Haematological and biochemical indices within the protocol specified ranges.
  6. Participants with advanced prostate cancer must have castrate levels of testosterone and have received a next generation hormonal agent (at least one of abiraterone, enzalutamide, apalutamide or darolutamide).
  7. Part A: Aged 16 years or over at the time consent is given.
  8. Part B Arm 1: Aged 18 years or over at the time consent is given.

Exclusion criteria

Exclusion criteria

  1. Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy (with the exception of life-long hormone suppression such as luteinising hormone-releasing hormone agents in prostate cancer), immunotherapy or medicinal products during the previous 4 weeks before first dose of HMBD-001 or enzalutamide, as applicable.
  2. Participants with ongoing toxic manifestations of previous treatments greater than Grade 1. Exceptions apply.
  3. Participants with symptomatic brain or should be excluded. Exceptions apply.
  4. Women of (or are already pregnant or lactating). Exceptions apply.
  5. Male participants with partners of child-bearing potential. Exceptions apply.
  6. Major surgery from which the participant has not yet recovered.
  7. At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
  8. Known to be serologically positive for , or infection. Participants with previous hepatitis C exposure but no current infection are eligible to participate.
  9. Known or suspected reaction to previous biological therapy that in the opinion of the Investigator is a for their participation in this study.
  10. Concurrent congestive heart failure, prior history of ≥ Class II cardiac disease (), cardiac ischaemia or clinically significant cardiac arrhythmia. Participants with significant cardiovascular disease as defined in the protocol are excluded.
  11. Active disease. Exceptions apply.
  12. Participants receiving doses of prednisolone ˃10 mg daily (or equipotent doses of other ) within 7 days prior to the first dose of study drug are not eligible unless administered as pre-medication.
  13. Participants having received a within 4 weeks prior to first dose of HMBD-001.
  14. Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase 1/2a trial of HMBD-001. Participation in an observational trial or interventional clinical trial which does not involve administration of an IMP and which would not place an unacceptable burden on the participant in the opinion of the Investigator and Medical Advisor would be acceptable.
  15. Any other condition which in the Investigator's opinion would not make the participant a good candidate for the clinical trial.
  16. Current or prior which could affect safety or efficacy assessment of the IMP or compliance with the protocol or interpretation of results. Participants with curatively-treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinomas-in-situ are generally eligible.

    Part B Arm 1: HMBD-001 and Enzalutamide Combination:

  17. Participants receiving warfarin or coumarin-like anti-coagulants.
  18. History of seizures or other risk factors for the development of seizures e.g. prior history of stroke, brain injury, , leptomeningeal disease.
  19. Participants with hypersensitivity to enzalutamide or any of the
  20. Participants who have received prior enzalutamide or other next generation hormonal agent that has been stopped due to toxicities or intolerance or required a dose reduction during administration due to toxicity or intolerance.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    HMBD-001 (Part A)

    Drug: HMBD-001

  • Experimental
    HMBD-001 and enzalutamide (Part B Arm 1)

    Drug: HMBD-001 and enzalutamide

Interventions

  • DrugHMBD-001

    Participants with advanced solid tumours will receive their assigned dose level of HMBD-001 diluted in 0.9% sodium chloride, administered once a week as a 120-minute intravenous (IV) infusion. Cycles are 28 days with no break in between; administration may continue for up to 6 cycles but may continue for longer if the participant is deemed to be benefitting.

  • DrugHMBD-001 and enzalutamide

    Drug page: EnzalutamideStudies of EnzalutamideEnzalutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants with metastatic castration resistant prostate cancer (mCRPC) confirmed as HER3 positive with no PTEN loss or with a NRG1 fusion rearrangement will receive the HMBD-001 recommended Phase 2 dose (RP2D) as determined in Part A, diluted in 0.9% sodium chloride and administered once a week as a 120-minute IV infusion, in combination with enzalutamide administered at a fixed dose of 160 mg once daily, in 28-day cycles with no break between cycles. Immediately before commencing combination therapy, participants may receive one 28-day cycle of enzalutamide monotherapy to confirm that their disease does not respond to enzalutamide alone. HMBD-001 may be administered for up to 6 cycles; enzalutamide may be continued until disease progression or unacceptable toxicity.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Dose Limiting Toxicities (DLTs); Part A

    DLTs graded for severity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0, measured by count of participants per arm.

    Time frame: From first dose onwards until completion of Cycle 1 (28 days)

  2. Number of Participants Who Experienced DLTs; Part B Arm 1

    DLTs graded for severity using the NCI CTCAE v5.0, measured by count of participants per arm.

    Time frame: From first dose of combination therapy onwards until completion of Cycle 1 (28 days)

  3. Number of adverse events (AEs) by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1)

    Number of AEs related to HMBD-001 given as a single agent and in combination with enzlutamide, graded according to NCI CTCAE v5.0.

    Time frame: From the date of written informed consent until the end of the safety follow-up period (maximum [max] 42 weeks per participant)

  4. Number of Grade 3, 4 and 5 AEs by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1)

    Number of Grade 3, 4 and 5 AEs related to HMBD-001 given as a single agent and in combination with enzalutamide, graded according to NCI CTCAE v5.0.

    Time frame: From the date of written informed consent until the end of the safety follow-up period (max 42 weeks per participant)

  5. Overall response rate (ORR) within 6 cycles of HMBD-001 (Part B Arm 1)

    Proportion of participants who achieve a best response of complete response (CR) or partial response (PR), based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 and/or Prostate Cancer Working Group 3 (PCWG3) Criteria as applicable, within 6 cycles of HMBD-001 in combination with enzalutamide.

    Time frame: From baseline radiological disease assessment until 28 days after last dose of HMBD-001 (max 36 weeks per participant)

Secondary outcomes

  1. ORR within 6 cycles of HMBD-001 (Part A)

    Proportion of participants who achieve a best response of CR or PR, based on RECIST v1.1 and/or PCWG3 Criteria as applicable, within 6 cycles of HMBD-001 monotherapy.

    Time frame: From baseline radiological disease assessment until 28 days after last dose of HMBD-001 (max 32 weeks per participant)

  2. Maximum observed serum concentration (Cmax) of HMBD-001 (Part A and Part B Arm 1)

    Cmax of HMBD-001 in serum, analysed via enzyme linked immunosorbent assay (ELISA). Not all participants will be analysed at all timepoints.

    Time frame: Up to 31 timepoints from first dose until 28 days after the last dose of HMBD-001 (max 28 weeks per participant)

  3. Minimum observed serum concentration (Cmin) of HMBD-001 (Part A and Part B Arm 1)

    Cmin of HMBD-001 in serum, analysed via ELISA. Not all participants will be analysed at all timepoints.

    Time frame: Up to 31 timepoints from first dose until 28 days after the last dose of HMBD-001 (max 28 weeks per participant)

  4. Area under the serum concentration-time curve (AUC) of HMBD-001 (Part A and Part B Arm 1)

    AUC of HMBD-001, analysed via ELISA. Not all participants will be analysed at all timepoint

    Time frame: Up to 31 timepoints from first dose until 28 days after the last dose of HMBD-001 (max 28 weeks per participant)

  5. Terminal elimination half-life (t½) of HMBD-001 (Part A and Part B Arm 1)

    t½ of HMBD-001 in serum, analysed via ELISA. Not all participants will be analysed at all timepoints.

    Time frame: Up to 31 timepoints from first dose until 28 days after the last dose of HMBD-001 (max 28 weeks per participant)

  6. Steady state volume of distribution of HMBD-001 in serum (Part A and Part B Arm 1)

    Volume of distribution of HMBD-001 in serum at steady state, analysed via ELISA. Not all participants will be analysed at all timepoints.

    Time frame: Up to 31 timepoints from first dose until 28 days after the last dose of HMBD-001 (max 28 weeks per participant)

  7. Total body clearance of HMBD-001 (Part A and Part B Arm 1)

    Total body clearance of HMBD-001 measured in serum, analysed via ELISA. Not all participants will be analysed at all timepoints.

    Time frame: Up to 31 timepoints from first dose until 28 days after the last dose of HMBD-001 (max 28 weeks per participant)

  8. ORR within 8 and 16 weeks of commencing HMBD-001 (Part A and Part B Arm 1)

    Proportion of participants achieving a best response of CR, or PR according to RECIST v1.1 and/or PCWG3 Criteria as applicable, within 8 and 16 weeks of commencing HMBD-001 as monotherapy and in combination with enzalutamide.

    Time frame: From baseline radiological disease assessment up to 16 weeks post first HMBD-001 administration (max 24 weeks per participant)

  9. Disease control rate within 6 cycles of HMBD-001 (Part A and Part B Arm 1)

    Proportion of participants achieving a best response of CR, PR or stable disease (SD), based on RECIST v1.1 and/or PCWG3 Criteria as applicable, within 6 cycles of HMBD-001 as monotherapy and in combination with enzalutamide.

    Time frame: From baseline radiological disease assessment up to 28 days post last HMBD-001 administration (max 36 weeks per participant)

  10. Duration of response (Part A and Part B Arm 1)

    The median duration in days from the first observation of a CR or PR, according to RECIST v1.1 and/or PCWG3 Criteria as applicable, until either progressive disease (PD) or death from any cause, in participants with a confirmed CR or PR.

    Time frame: From the date of first recorded response until 24 months after the last enrolled participant's first dose of HMBD-001 (max 48 months per participant)

  11. Duration of clinical benefit (Part A and Part B Arm 1)

    The median duration in days from the first administration of HMBD-001 until either PD or death from any cause, in participants who achieve a CR, PR, or SD for at least 24 weeks, according to RECIST v1.1 and/or PCWG3 Criteria as applicable.

    Time frame: From the date of first recorded response until 24 months after the last enrolled participant's first dose of HMBD-001(max 48 months per participant)

  12. Progression free survival (Part B Arm 1)

    The median duration in days from first dose of HMBD-001 to death from any cause or PD according to RECIST v1.1 and/or PCWG3 Criteria as applicable.

    Time frame: From first dose of HMBD-001 until 24 months after the last enrolled participant's first dose of HMBD-001 (max 48 months per participant)

  13. Overall survival (Part B Arm 1)

    The median time from first dose of HMBD-001 to death from any cause.

    Time frame: From first dose of HMBD-001 until 24 months after the last enrolled participant's first dose of HMBD-001 (max 48 months per participant)

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Nov 2025, 48 months after the start.

Of 67 phase 1/2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 78. This study's planned 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2021
First posted
Sep 27, 2021
StartActual
Nov 10, 2021
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05057013
Lead sponsor
Cancer Research UK
Collaborators
Hummingbird Bioscience
Responsible party
Sponsor
First posted
Sep 27, 2021
Start date
Nov 10, 2021
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Aug 11, 2025

Study contacts

Johann de Bono, Prof
principal investigator · Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion